Your browser doesn't support javascript.
loading
A phase 1 study of the antibody-drug conjugate brentuximab vedotin with re-induction chemotherapy in patients with CD30-expressing relapsed/refractory acute myeloid leukemia.
Narayan, Rupa; Blonquist, Traci M; Emadi, Ashkan; Hasserjian, Robert P; Burke, Meghan; Lescinskas, Christopher; Neuberg, Donna S; Brunner, Andrew M; Hobbs, Gabriela; Hock, Hanno; McAfee, Steven L; Chen, Yi-Bin; Attar, Eyal; Graubert, Timothy A; Bertoli, Christina; Moran, Jenna A; Bergeron, Meghan K; Foster, Julia E; Ramos, Aura Y; Som, Tina T; Vartanian, Megan K; Story, Jennifer L; McGregor, Kristin; Macrae, Molly; Behnan, Tanya; Wey, Margaret C; Rae, Jessica; Preffer, Frederic I; Lesho, Patricia; Duong, Vu H; Mann, Mason L; Ballen, Karen K; Connolly, Christine; Amrein, Philip C; Fathi, Amir T.
Afiliación
  • Narayan R; Division of Hematology/Oncology, Massachusetts General Hospital, Boston, Massachusetts.
  • Blonquist TM; Division of Biostatistics, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Emadi A; Division of Hematology/Oncology, University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center, Baltimore, Maryland.
  • Hasserjian RP; Division of Hematology/Oncology, Massachusetts General Hospital, Boston, Massachusetts.
  • Burke M; Division of Hematology/Oncology, Massachusetts General Hospital, Boston, Massachusetts.
  • Lescinskas C; Division of Hematology/Oncology, Massachusetts General Hospital, Boston, Massachusetts.
  • Neuberg DS; Division of Biostatistics, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Brunner AM; Division of Hematology/Oncology, Massachusetts General Hospital, Boston, Massachusetts.
  • Hobbs G; Division of Hematology/Oncology, Massachusetts General Hospital, Boston, Massachusetts.
  • Hock H; Division of Hematology/Oncology, Massachusetts General Hospital, Boston, Massachusetts.
  • McAfee SL; Division of Hematology/Oncology, Massachusetts General Hospital, Boston, Massachusetts.
  • Chen YB; Division of Hematology/Oncology, Massachusetts General Hospital, Boston, Massachusetts.
  • Attar E; Division of Hematology/Oncology, Massachusetts General Hospital, Boston, Massachusetts.
  • Graubert TA; Division of Hematology/Oncology, Massachusetts General Hospital, Boston, Massachusetts.
  • Bertoli C; Division of Hematology/Oncology, Massachusetts General Hospital, Boston, Massachusetts.
  • Moran JA; Division of Hematology/Oncology, Massachusetts General Hospital, Boston, Massachusetts.
  • Bergeron MK; Division of Hematology/Oncology, Massachusetts General Hospital, Boston, Massachusetts.
  • Foster JE; Division of Hematology/Oncology, Massachusetts General Hospital, Boston, Massachusetts.
  • Ramos AY; Division of Hematology/Oncology, Massachusetts General Hospital, Boston, Massachusetts.
  • Som TT; Division of Hematology/Oncology, Massachusetts General Hospital, Boston, Massachusetts.
  • Vartanian MK; Division of Hematology/Oncology, Massachusetts General Hospital, Boston, Massachusetts.
  • Story JL; Division of Hematology/Oncology, Massachusetts General Hospital, Boston, Massachusetts.
  • McGregor K; Division of Hematology/Oncology, Massachusetts General Hospital, Boston, Massachusetts.
  • Macrae M; Division of Hematology/Oncology, Massachusetts General Hospital, Boston, Massachusetts.
  • Behnan T; Division of Hematology/Oncology, Massachusetts General Hospital, Boston, Massachusetts.
  • Wey MC; Division of Hematology/Oncology, Massachusetts General Hospital, Boston, Massachusetts.
  • Rae J; Division of Hematology/Oncology, Massachusetts General Hospital, Boston, Massachusetts.
  • Preffer FI; Division of Hematology/Oncology, Massachusetts General Hospital, Boston, Massachusetts.
  • Lesho P; Division of Hematology/Oncology, University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center, Baltimore, Maryland.
  • Duong VH; Division of Hematology/Oncology, University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center, Baltimore, Maryland.
  • Mann ML; Division of Hematology/Oncology, Massachusetts General Hospital, Boston, Massachusetts.
  • Ballen KK; Division of Hematology/Oncology, Massachusetts General Hospital, Boston, Massachusetts.
  • Connolly C; Division of Hematology/Oncology, Massachusetts General Hospital, Boston, Massachusetts.
  • Amrein PC; Division of Hematology/Oncology, Massachusetts General Hospital, Boston, Massachusetts.
  • Fathi AT; Division of Hematology/Oncology, Massachusetts General Hospital, Boston, Massachusetts.
Cancer ; 126(6): 1264-1273, 2020 03 15.
Article en En | MEDLINE | ID: mdl-31860140
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Leucemia Mieloide Aguda / Protocolos de Quimioterapia Combinada Antineoplásica / Inmunoconjugados / Quimioterapia de Inducción / Antineoplásicos Inmunológicos / Brentuximab Vedotina Tipo de estudio: Prognostic_studies Límite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Cancer Año: 2020 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Leucemia Mieloide Aguda / Protocolos de Quimioterapia Combinada Antineoplásica / Inmunoconjugados / Quimioterapia de Inducción / Antineoplásicos Inmunológicos / Brentuximab Vedotina Tipo de estudio: Prognostic_studies Límite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Cancer Año: 2020 Tipo del documento: Article